Zealand Pharma's 10% Weight Loss Drug Fails Market's Ruthless Efficacy Test

Zealand Pharma's experimental obesity drug worked. Patients lost more than a tenth of their body weight over 42 weeks. Yet the market responded with immediate, merciless punishment, erasing nearly £1 billion in value within hours. In today's obesity pharmaceutical landscape, clinical efficacy alone no longer suffices—treatments must beat Eli Lilly's benchmarks or face binary rejection.

The new efficacy threshold

Eli Lilly has become the de facto benchmark in obesity drug development, setting a bar that competitors must clear rather than simply approach. Zealand's petrelintide, developed in partnership with Roche, enrolled 493 participants and demonstrated meaningful weight reduction. A decade ago, a drug achieving double-digit weight loss might have been considered a commercial success.

Analysts at Jefferies acknowledged that petrelintide showed 'potential for Wegovy-like efficacy, but with placebo-like tolerability', suggesting the drug could represent 'a viable drug, though likely viewed as 2nd-best to Lilly's elora for now'. That qualifier—'placebo-like tolerability'—merits attention. Obesity medications have been plagued by side effects severe enough to force many patients to discontinue treatment.

Enjoying this article?

Get stories like this in your inbox every week.

Join the Community

A drug offering substantial weight loss with fewer adverse effects could serve a meaningful patient population. Investors, however, aren't pricing in that nuance. The question is whether the market's winner-takes-all mentality will ultimately constrain treatment options for patients who might benefit from alternatives with different safety profiles or mechanisms of action.

Not every patient responds identically to the same medication, yet capital is flowing exclusively toward drugs that post the highest headline efficacy numbers.

Even giants aren't immune

Zealand isn't the first casualty of this dynamic. In February, Novo Nordisk—the company that transformed the obesity drug landscape with Wegovy—saw its shares plummet more than 15% in a single trading session after its next-generation treatment CagriSema underperformed against Eli Lilly's tirzepatide. The trial was specifically designed to demonstrate that CagriSema was at least as effective as tirzepatide, but failed to meet that endpoint.

That single miss has proven extraordinarily costly. Novo Nordisk, which reached a valuation exceeding $600 billion in 2024 following Wegovy's commercial success, has since shed approximately $400 billion in market value. The shares have retreated to levels last seen before Wegovy elevated the Danish pharmaceutical company to the position of world's most valuable drugmaker.

Analysts at J.P. Morgan described the CagriSema results as 'a significant setback that could curb demand' and leave Novo 'struggling to win back share in the fast-growing obesity treatment market'. Their assessment was blunt: 'While CagriSema could offer a new treatment option to patients, the inferiority to Zepbound means it is unlikely to help Novo retake market share in obesity.'

The commercial cost of clinical nuance

What's particularly striking about these market reactions is the dissonance between clinical and commercial valuations. Zealand's petrelintide achieved 10.7% weight loss over 42 weeks. According to research published across multiple clinical studies, sustained weight loss of even 5-10% produces meaningful health benefits, including improved cardiovascular markers, reduced diabetes risk, and decreased joint stress.

But efficacy relative to zero treatment isn't the relevant comparison anymore. The relevant comparison is efficacy relative to Eli Lilly's pipeline, which has effectively set a moving target that keeps rising. This creates a pharmaceutical arms race where incremental improvements in mechanism or safety profile are valued at essentially zero unless accompanied by superior weight-loss percentages.

If capital allocation becomes entirely concentrated around the highest-efficacy candidates, pharmaceutical companies may deprioritise drugs with better tolerability profiles or novel mechanisms that serve specific patient subgroups.

The obesity market is enormous—affecting hundreds of millions globally—yet investor behaviour suggests they're backing a handful of treatments to dominate across all patient segments. Whether this proves sustainable depends largely on how the next wave of clinical data breaks. Eli Lilly has established clear leadership, but drug development remains unpredictable.

Safety concerns, manufacturing constraints, or regulatory challenges could shift the landscape rapidly. More importantly, physicians ultimately prescribe based on individual patient needs, not investor sentiment. A drug that delivers 10% weight loss with minimal side effects may find its market regardless of whether public shareholders value the company developing it.

Zealand's experience offers a cautionary signal for biotech firms pursuing obesity treatments: the market is no longer rewarding participation. Only the efficacy leaders will capture valuations that reflect the commercial opportunity ahead.

More articles by Ross Williams